Bloom Burton Comments on BioSyent Inc.’s Q4 2024 Earnings (CVE:RX)

BioSyent Inc. (CVE:RX) – Equities research analysts at Bloom Burton upped their Q4 2024 EPS estimates for shares of BioSyent in a research report issued on Monday, September 23rd. Bloom Burton analyst D. Martin now anticipates that the company will post earnings of $16.00 per share for the quarter, up from their prior estimate of $0.15. The consensus estimate for BioSyent’s current full-year earnings is $0.68 per share.

BioSyent (CVE:RX) last issued its quarterly earnings data on Monday, August 26th. The company reported C$0.13 earnings per share for the quarter, meeting analysts’ consensus estimates of C$0.13. The firm had revenue of C$8.95 million during the quarter, compared to analyst estimates of C$8.80 million. BioSyent had a return on equity of 20.88% and a net margin of 21.14%.

BioSyent Stock Performance

CVE RX opened at C$11.00 on Thursday. The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91. BioSyent has a 1-year low of C$7.66 and a 1-year high of C$11.45. The business has a 50 day simple moving average of C$10.39 and a two-hundred day simple moving average of C$9.53. The stock has a market capitalization of C$127.49 million, a PE ratio of 18.33 and a beta of 0.93.

Insider Activity

In related news, Director Seyed Ahmad Ashrafi sold 2,320 shares of the company’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of C$10.95, for a total transaction of C$25,404.00. In related news, Director Seyed Ahmad Ashrafi sold 2,320 shares of the stock in a transaction on Friday, September 20th. The stock was sold at an average price of C$10.95, for a total transaction of C$25,404.00. Also, insider FAX Capital Corp. sold 500,000 shares of the stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of C$10.05, for a total transaction of C$5,025,000.00. In the last ninety days, insiders sold 503,343 shares of company stock worth $5,061,311. 34.21% of the stock is currently owned by insiders.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.